Table 2.
Treatment Characteristics, Primary and Secondary Outcomes
| First author (year) | Treatment arm | Patients with active perianal disease | Patients with complete healing of fistulizing disease | Patients at least partial healing of fistulizing disease | Dose escalation regimen | Patients requiring dose escalation | Additional therapy (antibiotics or surgery) |
|---|---|---|---|---|---|---|---|
| Pestour (2018) [17] | Standard dose VDZ induction and maintenancea | 29 | 5 (17) | NR (assumed to be same 5 patients with complete healing) | If no clinical response at week 6, additional infusion of 300 mg VDZ at week 10, and then once every 4 weeks | NR | NR |
| Feagan (2018) [16] | Standard dose VDZ induction, maintenance with dosing either every 4 weeks or every 8 weeks, both groups combineda | 39 | 12 (31) | NR (assumed to be same 12 patients with | None | None | Medical treatment (antibiotics) for 21/39 |
| VDZ induction, followed by placebo maintenance | 18 | 2 (11) | NR (assumed to be same 2 patients with complete healing) | ||||
| Chapuis-Biron (2019) [11] | Standard dose VDZ induction and maintenancea | 102 | 23 (23) | 39 (38) | Patients requiring escalation had 300 mg intravenously every 4 or 6 weeks or 600 mg every 8 weeks | 62 | Medical treatment (antibiotics) for 39/102 (38%) patients and surgical treatment for 41/102 (40%) patients |
| Schwartz (2020) [12] | VDZ 300 mg IV at weeks (0, 2, 6, 14, and 22) | 14 | 7 (50) | 9 (64.3) | None | None | NR |
| The same regimen plus an additional VDZ dose at week 10 | 14 | 5 (35.7) | 6 (42.9) |
Values are presented as number or number (%).
a
VDZ 300 mg IV at weeks 0, 2, 6 (induction) and then every 8 weeks thereafter (maintenance).
VDZ, vedolizumab; IV, intravenous; NR, not reported.